Jinghua Pharmaceutical Group (SHE:002349) subsidiary Jinghua Nantong obtained the approval of China's medical products administrator to market its Ritonavir active pharmaceutical ingredient.
The API is used in HIV/AIDS treatment and in COVID-19 therapies, according to a filing with the Shenzhen bourse.
Shares of the pharmaceutical company closed 1% lower Friday.